HER2-targeted therapy
作者： Phuong Dinh , Gianluca Tomasello , Martine J. Piccart
DOI: 10.1007/978-3-540-69743-5_20
关键词: Oncology 、 Disease process 、 Targeted therapy 、 Pertuzumab 、 Epidermal growth factor receptor 、 Internal medicine 、 Aggressive phenotype 、 Lapatinib 、 Medicine 、 Immunology 、 Trastuzumab 、 Breast cancer
摘要: The HER2+ subtype of breast cancer represents less than 25 % incident cancers, and traditionally has been regarded as having the more aggressive phenotype, higher recurrence rates, reduced survival. HER2 landscape changed dramatically since discovery trastuzumab have resulted in much improved long-term outcomes for affected patients. is a validated therapeutic target that remains relevant throughout disease process. Recently, number novel targeted agents become available which provide additional treatment options patients with cancer. This chapter will discuss evolution HER2-targeted therapy, beginning initial success to controversies remain, from there, discussion newer anti-HER2 approaches currently under investigation.
springer.com
ulb.ac.be
core.ac.uk
sci-hub.st 参考文章(113)
Y Yarden, The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. European Journal of Cancer. ,vol. 37, pp. 3- 8 ,(2001) , 10.1016/S0959-8049(01)00230-1
Richard J. Pietras, David Gallardo, P. Nancy Wongvipat, H. Julie Lee, Joseph C. Poen, Dennis J. Slamon, Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Research. ,vol. 59, pp. 1347- 1355 ,(1999)
Brian Fendly, Mien Chie Hung, Robert S. Kerbel, Alicia M. Viloria Petit, Patricia Rockwell, Neil Goldstein, Janusz Rak, Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. American Journal of Pathology. ,vol. 151, pp. 1523- 1530 ,(1997)
Eric P. Winer, Harold J. Burstein, Irene Kuter, Susana M. Campos, Rebecca S. Gelman, Laura Tribou, Leroy M. Parker, Judith Manola, Jerry Younger, Ursula Matulonis, Craig A. Bunnell, Ann H. Partridge, Paul G. Richardson, Kathryn Clarke, Lawrence N. Shulman, Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer Journal of Clinical Oncology. ,vol. 19, pp. 2722- 2730 ,(2001) , 10.1200/JCO.2001.19.10.2722
M F Press, L Bernstein, P A Thomas, L F Meisner, J Y Zhou, Y Ma, G Hung, R A Robinson, C Harris, A El-Naggar, D J Slamon, R N Phillips, J S Ross, S R Wolman, K J Flom, HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. Journal of Clinical Oncology. ,vol. 15, pp. 2894- 2904 ,(1997) , 10.1200/JCO.1997.15.8.2894
G. Von Minckwitz, C. Zielinski, E. Maarteense, P. Vogel, M. Schmidt, H. Eidtmann, T. Cufer, F. E. de Jongh, M. Kaufmann, S. Loibl, Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05) Journal of Clinical Oncology. ,vol. 26, pp. 1025- 1025 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.1025
Joan Albanell, Larry Norton, Jose Baselga, Young Mee Kim, John Mendelsohn, Recombinant Humanized anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin Against HER2/neu Overexpressing Human Breast Cancer Xenografts Cancer Research. ,vol. 58, pp. 2825- 2831 ,(1998)
M. Beeram, I. Krop, S. Modi, A. Tolcher, N. Rabbee, S. Girish, J. Tibbitts, S. Holden, S. Lutzker, H. Burris, A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC) Journal of Clinical Oncology. ,vol. 25, pp. 1042- 1042 ,(2007) , 10.1200/JCO.2007.25.18_SUPPL.1042
D Slamon, W Eiermann, N Robert, T Pienkowski, M Martin, J Rolski, A Chan, J Mackey, M Liu, T Pinter, V Valero, C Falkson, T Fornander, T Shiftan, S Olsen, M Buyse, T Kiskartalyi, V Landreau, V Wilson, M Press, J Crown, BCIRG006 Investigators, Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. Cancer Research. ,vol. 69, pp. 62- 62 ,(2009) , 10.1158/0008-5472.SABCS-09-62
Rita Nahta, Takeshi Takahashi, Naoto T. Ueno, Mien-Chie Hung, Francisco J. Esteva, P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells Cancer Research. ,vol. 64, pp. 3981- 3986 ,(2004) , 10.1158/0008-5472.CAN-03-3900